TGAN vs. AIP, VLN, SKYT, NVEC, CAN, AAOI, MX, QUIK, AXTI, and ATOM
Should you be buying Transphorm stock or one of its competitors? The main competitors of Transphorm include Arteris (AIP), Valens Semiconductor (VLN), SkyWater Technology (SKYT), NVE (NVEC), Canaan (CAN), Applied Optoelectronics (AAOI), Magnachip Semiconductor (MX), QuickLogic (QUIK), AXT (AXTI), and Atomera (ATOM). These companies are all part of the "semiconductors & related devices" industry.
Arteris (NASDAQ:AIP) and Transphorm (NASDAQ:TGAN) are both small-cap computer and technology companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.
Arteris has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Transphorm has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.
64.4% of Arteris shares are owned by institutional investors. Comparatively, 66.5% of Transphorm shares are owned by institutional investors. 33.7% of Arteris shares are owned by insiders. Comparatively, 2.5% of Transphorm shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Arteris currently has a consensus price target of $13.40, suggesting a potential upside of 66.05%. Transphorm has a consensus price target of $5.75, suggesting a potential upside of 17.35%. Given Transphorm's stronger consensus rating and higher probable upside, equities analysts plainly believe Arteris is more favorable than Transphorm.
In the previous week, Arteris had 8 more articles in the media than Transphorm. MarketBeat recorded 11 mentions for Arteris and 3 mentions for Transphorm. Arteris' average media sentiment score of 0.94 beat Transphorm's score of 0.63 indicating that Transphorm is being referred to more favorably in the news media.
Arteris received 13 more outperform votes than Transphorm when rated by MarketBeat users. Likewise, 57.69% of users gave Arteris an outperform vote while only 50.00% of users gave Transphorm an outperform vote.
Transphorm has lower revenue, but higher earnings than Arteris. Arteris is trading at a lower price-to-earnings ratio than Transphorm, indicating that it is currently the more affordable of the two stocks.
Arteris has a net margin of -69.70% compared to Arteris' net margin of -177.91%. Arteris' return on equity of -149.03% beat Transphorm's return on equity.
Summary
Arteris beats Transphorm on 11 of the 18 factors compared between the two stocks.
Get Transphorm News Delivered to You Automatically
Sign up to receive the latest news and ratings for TGAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TGAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Transphorm Competitors List
Related Companies and Tools
